FATE FATE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, FATE THERAPEUTICS INC reported revenue of $2.08M (up 9.2% from a year earlier), net income of −$30.2M and diluted EPS of −$0.25; over the last four quarters revenue was $6.49M and net income −$126M; for the fiscal year ended December 2025 revenue was $6.65M, down 51.2% on the year before.

FATE annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $6.65M, gross profit n/a, operating income −$148M, net income −$136M (margin -2051.1%), EPS −$1.15
• Fiscal year ended Dec 2024: revenue $13.6M, gross profit n/a, operating income −$210M, net income −$186M (margin -1366.5%), EPS −$1.64
• Fiscal year ended Dec 2023: revenue $63.5M, gross profit n/a, operating income −$191M, net income −$161M (margin -253.3%), EPS −$1.64
• Fiscal year ended Dec 2022: revenue $96.3M, gross profit n/a, operating income −$308M, net income −$282M (margin -292.5%), EPS −$2.91
• Fiscal year ended Dec 2021: revenue $55.8M, gross profit n/a, operating income −$217M, net income −$212M (margin -379.9%), EPS −$2.24

FATE quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $2.08M (up 9.2% year over year), net income −$30.2M, EPS −$0.25
• Quarter ended Mar 31, 2026: revenue $1.30M (down 20.3% year over year), net income −$31.2M, EPS −$0.26
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.37M (down 26.4% year over year), net income −$32.4M, EPS −$0.27
• Quarter ended Sep 30, 2025: revenue $1.74M (down 43.4% year over year), net income −$32.3M, EPS −$0.27
• Quarter ended Jun 30, 2025: revenue $1.91M (down 71.8% year over year), net income −$34.1M, EPS −$0.29
• Quarter ended Mar 31, 2025: revenue $1.63M (down 15.4% year over year), net income −$37.6M, EPS −$0.32
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.86M (up 11.0% year over year), net income −$52.2M, EPS −$0.44
• Quarter ended Sep 30, 2024: revenue $3.07M (up 58.1% year over year), net income −$47.7M, EPS −$0.40
• Quarter ended Jun 30, 2024: revenue $6.77M (up 625.8% year over year), net income −$38.4M, EPS −$0.33
• Quarter ended Mar 31, 2024: revenue $1.93M (down 96.7% year over year), net income −$48.0M, EPS −$0.47
• Quarter ended Dec 31, 2023 (from the annual report): revenue $1.68M (down 96.2% year over year), net income −$44.1M, EPS −$0.45
• Quarter ended Sep 30, 2023: revenue $1.94M (down 87.0% year over year), net income −$45.2M, EPS −$0.46
• Quarter ended Jun 30, 2023: revenue $933K (down 95.0% year over year), net income −$52.8M, EPS −$0.54
• Quarter ended Mar 31, 2023: revenue $59.0M (up 220.3% year over year), net income −$18.9M, EPS −$0.19
• Quarter ended Dec 31, 2022 (from the annual report): revenue $44.4M (up 159.9% year over year), net income −$56.4M, EPS −$0.58
• Quarter ended Sep 30, 2022: revenue $15.0M (up 5.3% year over year), net income −$83.6M, EPS −$0.86
• Quarter ended Jun 30, 2022: revenue $18.5M (up 38.3% year over year), net income −$76.1M, EPS −$0.79
• Quarter ended Mar 31, 2022: revenue $18.4M (up 65.3% year over year), net income −$65.7M, EPS −$0.68
• Quarter ended Dec 31, 2021 (from the annual report): revenue $17.1M, net income −$68.6M, EPS −$0.73
• Quarter ended Sep 30, 2021: revenue $14.2M, net income −$43.3M, EPS −$0.45

FATE cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$106M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$123M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$132M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$248M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$163M, share buybacks n/a

FATE balance sheet

• Jun 30, 2026: cash $32.4M, total assets $260M, total liabilities n/a, shareholders' equity $153M
• Mar 31, 2026: cash $39.6M, total assets $285M, total liabilities n/a, shareholders' equity $180M
• Dec 31, 2025: cash $46.6M, total assets $319M, total liabilities n/a, shareholders' equity $207M
• Sep 30, 2025: cash $40.6M, total assets $344M, total liabilities n/a, shareholders' equity $234M
• Jun 30, 2025: cash $41.2M, total assets $372M, total liabilities n/a, shareholders' equity $261M
• Mar 31, 2025: cash $44.9M, total assets $399M, total liabilities n/a, shareholders' equity $288M
• Dec 31, 2024: cash $36.1M, total assets $441M, total liabilities n/a, shareholders' equity $319M
• Sep 30, 2024: cash $37.9M, total assets $495M, total liabilities n/a, shareholders' equity $362M

What is FATE's revenue?

FATE THERAPEUTICS INC reported $6.49M of revenue over its last four quarters, through June 30, 2026.

Is FATE profitable?

No. FATE THERAPEUTICS INC lost $126M over the last four quarters.

What is FATE's EPS?

Diluted earnings per share over the last four quarters were −$1.05; −$0.25 in the latest quarter.

FATE ownership and insider trades · All stocks